Harvard Chan Student Wins 3MT Competition with TB Research
Harvard graduate student Abigail Frey has been awarded first place in the university’s prestigious Three Minute Thesis (3MT) competition for her research into drug-resistant tuberculosis (TB). Frey, a student in the Biological Sciences in Public Health PhD program at the Harvard Chan School of Public Health, presented her work on how Mycobacterium tuberculosis evades antibiotic treatment and how this understanding can lead to faster, more accurate diagnoses. The competition, held on March 13, 2026, challenges researchers to distill complex projects into engaging three-minute presentations.
Tuberculosis remains a significant global health threat, claiming over a million lives in 2024, according to the World Health Organization (WHO fact sheet on Tuberculosis). A growing concern is the rise of drug-resistant strains, where standard treatments prove ineffective. Approximately 1 in 25 TB cases are drug resistant, necessitating more sophisticated diagnostic approaches.
Unlocking the Mechanisms of Antibiotic Escape
Frey’s research, conducted in the Fortune Lab under the guidance of Sarah Fortune, Chair of the Department of Immunology and Infectious Diseases, focuses on identifying the genetic mechanisms that allow TB bacteria to survive antibiotic exposure. Her work combines population genomics – the study of genetic variation within a population of bacteria – with bacterial genetics to pinpoint these “escape mechanisms.” As Harvard’s Graduate School of Arts and Sciences reports, the ultimate goal is to translate these findings into genetic diagnostics that can quickly and accurately identify drug resistance.
Currently, diagnosing drug-resistant TB relies on laboratory tests that can take weeks or even months to yield results. This delay can hinder effective treatment and contribute to the spread of infection. A faster, more precise diagnostic tool, based on identifying specific genetic mutations, could dramatically improve patient outcomes and control the spread of drug-resistant TB, particularly in low- and middle-income countries where the burden of the disease is highest.
The Promise of Genetic Diagnostics
The core of Frey’s research lies in understanding how TB bacteria develop resistance. Antibiotics work by targeting essential bacterial processes. However, bacteria are remarkably adaptable and can evolve mechanisms to circumvent these attacks. These mechanisms can include mutations that alter the drug’s target, reduce the drug’s ability to enter the bacterial cell, or actively pump the drug out. Identifying these specific mutations is crucial for developing effective diagnostic tests.
As Sarah Fortune explained, Frey’s research “is trying to define the novel antibiotic escape mechanisms by combining population genomics and bacterial genetics — which then helps build the roadmap for genetic diagnostics for patient use.” This roadmap, if successful, would allow clinicians to quickly determine which antibiotics will be effective against a patient’s specific strain of TB, leading to personalized treatment plans.
Beyond Diagnosis: Implications for Treatment Strategies
While the immediate focus of Frey’s work is on improving diagnostics, the insights gained could also inform the development of new treatment strategies. By understanding the mechanisms of antibiotic resistance, researchers can potentially design drugs that overcome these defenses or identify combinations of drugs that are more effective against resistant strains. This is particularly important given the limited number of new antibiotics currently in development.
The challenge with TB treatment isn’t simply finding drugs that kill the bacteria; it’s ensuring that the entire bacterial population is eradicated. Even a little number of surviving bacteria can develop resistance and lead to treatment failure. Frey’s research, by identifying the genetic factors that contribute to resistance, could assist optimize treatment regimens to minimize the risk of relapse and the emergence of further drug resistance.
The 3MT Competition and Communicating Science
The Three Minute Thesis competition is designed to cultivate the ability of researchers to communicate their work effectively to a non-specialist audience. This skill is increasingly important, as scientists are called upon to engage with policymakers, the media, and the public on complex scientific issues. Frey’s success in the competition highlights her ability to translate complex scientific concepts into a compelling and accessible narrative.
The competition itself is a rigorous process, requiring participants to condense years of research into a concise and engaging presentation. Judges evaluate presentations based on clarity, engagement, and the ability to convey the significance of the research. Frey’s win is a testament to the quality of her work and her skill as a communicator. You can find more information about the competition on the Harvard Chan School website.
What’s Next for TB Research and Diagnostics?
Frey’s work is part of a broader effort to combat drug-resistant TB globally. The World Health Organization has set ambitious targets for reducing TB incidence and mortality, including a commitment to ending the TB epidemic by 2030. Achieving these goals will require sustained investment in research, improved diagnostics, and expanded access to treatment. Ongoing surveillance of TB strains and antibiotic resistance patterns is also crucial for tracking the spread of drug-resistant strains and informing public health interventions.
Further research is needed to validate Frey’s findings and translate them into practical diagnostic tools. This will involve large-scale studies to confirm the association between specific genetic mutations and drug resistance, as well as the development of affordable and accessible diagnostic tests that can be deployed in resource-limited settings. The development of new antibiotics remains a critical priority, but in the meantime, optimizing existing treatments and improving diagnostics are essential steps in the fight against TB.